Posted August 28, 2019
Gemstone Biotherapeutics Receives Maryland Momentum Fund Investment
Gemstone Biotherapeutics, a clinical stage biotech company developing innovative, evidence-based products for scar-free skin regeneration, has received a $250,000 investment from the University System of Maryland (USM) Maryland Momentum Fund. The investment is part of Gemstone’s bridge funding round.
Each year, more than 30 million patients in the U.S. need a skin biopsy or excision to diagnose or treat skin disease. Gemstone’s products work with the body’s natural healing mechanisms to restore healthy, stretchy, scar-free skin. The platform technology has the potential to transform the dermatology market with high-impact, functional, and aesthetic benefits for patients and cost savings for the health care industry.